NASDAQ:RARE Ultragenyx Pharmaceutical (RARE) Stock Forecast, Price & News $51.25 +0.40 (+0.79%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$50.05▼$51.9350-Day Range$37.33▼$51.4252-Week Range$33.36▼$68.68Volume554,270 shsAverage Volume631,404 shsMarket Capitalization$3.63 billionP/E RatioN/ADividend YieldN/APrice Target$90.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ultragenyx Pharmaceutical MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside74.8% Upside$90.25 Price TargetShort InterestBearish5.32% of Float Sold ShortDividend StrengthN/ASustainability-2.28Upright™ Environmental ScoreNews Sentiment1.14Based on 7 Articles This WeekInsider TradingSelling Shares$297,610 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($8.35) to ($6.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector269th out of 985 stocksPharmaceutical Preparations Industry124th out of 488 stocks 3.4 Analyst's Opinion Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $90.25, Ultragenyx Pharmaceutical has a forecasted upside of 74.8% from its current price of $51.62.Amount of Analyst CoverageUltragenyx Pharmaceutical has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.32% of the float of Ultragenyx Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently increased by 17.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUltragenyx Pharmaceutical has received a 49.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Triheptanoin", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ultragenyx Pharmaceutical is -2.28. Previous Next 4.0 News and Social Media Coverage News SentimentUltragenyx Pharmaceutical has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Ultragenyx Pharmaceutical this week, compared to 3 articles on an average week.Search Interest3 people have searched for RARE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows8 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $297,610.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions93.17% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($8.35) to ($6.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUltragenyx Pharmaceutical has a P/B Ratio of 10.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ultragenyx Pharmaceutical (NASDAQ:RARE) StockUltragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.Read More Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Stock News HeadlinesMay 18, 2023 | marketbeat.comAnalysts Say These 2 Mid-Cap Biotechs Have 2x Potential (RARE)These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.June 2, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and QuidelOrtho (QDEL)June 5, 2023 | Altimetry (Ad)Surprising "Twist" Hands Biden Landslide Re-election?This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.May 31, 2023 | americanbankingnews.comShort Interest in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Increases By 17.1%May 24, 2023 | finanznachrichten.de3BL Alerts: Ultragenyx Issues 2022 ESG Report, Continuing To Enhance Its Leadership on Corporate ResponsibilityMay 24, 2023 | finance.yahoo.comUltragenyx Issues 2022 ESG Report, Continuing To Enhance Its Leadership on Corporate ResponsibilityMay 24, 2023 | finance.yahoo.comStrong week for Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders doesn't alleviate pain of three-year lossMay 22, 2023 | seekingalpha.comUltragenyx: Despite OI Trial Doubts, This Is A Robust Rare Disease CompanyJune 5, 2023 | Altimetry (Ad)Surprising "Twist" Hands Biden Landslide Re-election?This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.May 22, 2023 | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated at StockNews.comMay 20, 2023 | americanbankingnews.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 19, 2023 | finance.yahoo.comUltragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy SummitMay 15, 2023 | finance.yahoo.comUltragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS RatingMay 15, 2023 | msn.comUltragenyx Pharmaceutical's Return On Capital Employed InsightsMay 12, 2023 | americanbankingnews.comUltragenyx Pharmaceutical's (RARE) "Maintains" Rating Reiterated at 1-800-FLOWERS.COMMay 11, 2023 | americanbankingnews.comWedbush Brokers Boost Earnings Estimates for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 11, 2023 | americanbankingnews.comUltragenyx Pharmaceutical's (RARE) Maintains Rating Reiterated at 1-800-FLOWERS.COMMay 10, 2023 | americanbankingnews.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Forecasted to Earn Q2 2023 Earnings of ($1.77) Per ShareMay 9, 2023 | msn.comWedbush Maintains Ultragenyx Pharmaceutical (RARE) Neutral RecommendationMay 8, 2023 | finance.yahoo.comUltragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual MeetingMay 8, 2023 | markets.businessinsider.comWedbush Remains a Hold on Ultragenyx Pharmaceutical (RARE)May 7, 2023 | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down After Earnings MissMay 6, 2023 | msn.comCredit Suisse Reiterates Ultragenyx Pharmaceutical (RARE) Outperform RecommendationMay 5, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)May 5, 2023 | finance.yahoo.comUltragenyx (RARE) Q1 Earnings and Revenues Miss EstimatesMay 5, 2023 | finance.yahoo.comQ1 2023 Ultragenyx Pharmaceutical Inc Earnings CallMay 5, 2023 | finance.yahoo.comUltragenyx to Present at Bank of America’s 2023 Health Care ConferenceSee More Headlines RARE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RARE Company Calendar Last Earnings5/04/2023Today6/05/2023Next Earnings (Estimated)7/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RARE CUSIPN/A CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,311Year Founded2010Price Target and Rating Average Stock Price Forecast$90.25 High Stock Price Forecast$142.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+77.5%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($10.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-707,420,000.00 Net Margins-187.31% Pretax Margin-185.85% Return on Equity-149.75% Return on Assets-43.89% Debt Debt-to-Equity RatioN/A Current Ratio3.51 Quick Ratio3.39 Sales & Book Value Annual Sales$363.33 million Price / Sales9.91 Cash FlowN/A Price / Cash FlowN/A Book Value$5.03 per share Price / Book10.11Miscellaneous Outstanding Shares70,810,000Free Float65,999,000Market Cap$3.60 billion OptionableOptionable Beta0.90 Social Links Key ExecutivesEmil D. KakkisPresident, Chief Executive Officer & DirectorDennis Karl HuangChief Technical Operations Officer & Senior VPEric CrombezChief Medical Officer & Executive Vice PresidentSamuel C. WadsworthChief Scientific OfficerThomas Richard KassbergChief Business Officer & Executive Vice PresidentKey CompetitorsBlueprint MedicinesNASDAQ:BPMCProthenaNASDAQ:PRTAReata PharmaceuticalsNASDAQ:RETAArrowhead PharmaceuticalsNASDAQ:ARWRCytokineticsNASDAQ:CYTKView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Sold 182,222 shares on 6/1/2023Ownership: 1.343%ProShare Advisors LLCSold 1,423 shares on 5/26/2023Ownership: 0.008%Ameriprise Financial Inc.Bought 20,312 shares on 5/22/2023Ownership: 0.083%JPMorgan Chase & Co.Sold 6,087 shares on 5/18/2023Ownership: 0.409%John Richard PinionSold 2,012 sharesTotal: $100,600.00 ($50.00/share)View All Insider TransactionsView All Institutional Transactions RARE Stock - Frequently Asked Questions Should I buy or sell Ultragenyx Pharmaceutical stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RARE shares. View RARE analyst ratings or view top-rated stocks. What is Ultragenyx Pharmaceutical's stock price forecast for 2023? 12 equities research analysts have issued 1 year target prices for Ultragenyx Pharmaceutical's shares. Their RARE share price forecasts range from $50.00 to $142.00. On average, they expect the company's stock price to reach $90.25 in the next twelve months. This suggests a possible upside of 74.8% from the stock's current price. View analysts price targets for RARE or view top-rated stocks among Wall Street analysts. How have RARE shares performed in 2023? Ultragenyx Pharmaceutical's stock was trading at $46.33 at the beginning of the year. Since then, RARE stock has increased by 11.4% and is now trading at $51.62. View the best growth stocks for 2023 here. Are investors shorting Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 3,490,000 shares, an increase of 17.1% from the April 30th total of 2,980,000 shares. Based on an average daily volume of 637,500 shares, the short-interest ratio is presently 5.5 days. Currently, 5.3% of the shares of the stock are sold short. View Ultragenyx Pharmaceutical's Short Interest. When is Ultragenyx Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023. View our RARE earnings forecast. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its earnings results on Thursday, May, 4th. The biopharmaceutical company reported ($2.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.97) by $0.36. The biopharmaceutical company had revenue of $100.50 million for the quarter, compared to analysts' expectations of $103.90 million. Ultragenyx Pharmaceutical had a negative net margin of 187.31% and a negative trailing twelve-month return on equity of 149.75%. The firm's quarterly revenue was up 25.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.19) EPS. What ETFs hold Ultragenyx Pharmaceutical's stock? ETFs with the largest weight of Ultragenyx Pharmaceutical (NASDAQ:RARE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), Motley Fool Mid-Cap Growth ETF (TMFM) and SPDR S&P Biotech ETF (XBI). What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings? Ultragenyx Pharmaceutical updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $425.00 million-$450.00 million, compared to the consensus revenue estimate of $435.57 million. What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO? 41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM). What is Ultragenyx Pharmaceutical's stock symbol? Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE." Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (7.22%), BlackRock Inc. (6.90%), RTW Investments LP (6.04%), Price T Rowe Associates Inc. MD (5.01%), State Street Corp (3.89%) and Clearbridge Investments LLC (3.82%). Insiders that own company stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ultragenyx Pharmaceutical's stock price today? One share of RARE stock can currently be purchased for approximately $51.62. How much money does Ultragenyx Pharmaceutical make? Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $3.66 billion and generates $363.33 million in revenue each year. The biopharmaceutical company earns $-707,420,000.00 in net income (profit) each year or ($10.25) on an earnings per share basis. How many employees does Ultragenyx Pharmaceutical have? The company employs 1,311 workers across the globe. How can I contact Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for the company is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810. This page (NASDAQ:RARE) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.